COX-2s pending approval may also carry heart risks

Share this article:
The FDA suggested two COX-2 drugs pending approval, Merck's Arcoxia and Novartis' Prexige, carry similar cardiovascular risks to Merck's Vioxx.
The FDA raised questions about the drugs in staff documents posted ahead of this week's joint-session on COX-2s to examine their risks and benefits.
The FDA said in the documents that there was an increase in the number of cardiovascular events and hypertension in people using Arcoxia.
The documents also said a study involving patients taking Prexige and patients taking naproxen showed there was an increase in the number of cardiac deaths and non-fatal heart attacks and strokes among those taking Prexige.
Share this article:

Email Newsletters

More in Business Briefs

Biologics have higher psoriatic arthritis adherence

A study of psoriatic arthritis patients found greater adherence among patients whose initial treatment was a biologic, compared to those who started with a non-biologic treatment.

IRS struggles with device tax

A Treasury report says the IRS is having trouble identifying who owes it money.

White House proposes Hobby Lobby alternative

A proposal by the Obama administration Friday seeks to keep contraception accessible and coverage approval at arm's length for employees of religious non-profits.